SIGA - NASDAQ
SIGA Technologies, Inc.
$4.29
-0.69%SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
At a Glance
Live SnapshotSIGA Technologies, Inc. Management Team
Dr. Diem Nguyen M.B.A., Ph.D.
Chief Executive Officer & Director
Compensation
$1,735,384
Dr. Dennis E. Hruby Ph.D.
Executive Vice President & Chief Scientific Officer
Compensation
$1,453,450
Mr. Daniel J. Luckshire CPA, M.B.A.
Executive Vice President, Chief Financial Officer & Secretary
Compensation
$1,460,684
Mr. Lawrence R. Miller Esq., J.D.
General Counsel & Corporate Secretary
Compensation
$1,014,948
Mr. Herb Vloedman
Senior Vice President & Chief Information Officer
Ms. Tove C. Bolken
Senior Vice President of Operations & Chief Supply Chain Officer
SIGA Technologies, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for SIGA.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
SIGA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 26, 2023 | April 26, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | May 21, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 18, 2018 | May 22, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 17, 2017 | May 23, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.